A BSL-4 high-throughput screen identifies sulfonamide inhibitors of Nipah virus

Bersabeh Tigabu, Lynn Rasmussen, E. Lucile White, Nichole Tower, Mohammad Saeed, Alexander Bukreyev, Barry Rockx, James LeDuc, James W. Noah

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Nipah virus is a biosafety level 4 (BSL-4) pathogen that causes severe respiratory illness and encephalitis in humans. To identify novel small molecules that target Nipah virus replication as potential therapeutics, Southern Research Institute and Galveston National Laboratory jointly developed an automated high-throughput screening platform that is capable of testing 10,000 compounds per day within BSL-4 biocontainment. Using this platform, we screened a 10,080-compound library using a cell-based, high-throughput screen for compounds that inhibited the virus-induced cytopathic effect. From this pilot effort, 23 compounds were identified with EC50 values ranging from 3.9 to 20.0 μM and selectivities >10. Three sulfonamide compounds with EC50 values <12 μM were further characterized for their point of intervention in the viral replication cycle and for broad antiviral efficacy. Development of HTS capability under BSL-4 containment changes the paradigm for drug discovery for highly pathogenic agents because this platform can be readily modified to identify prophylactic and postexposure therapeutic candidates against other BSL-4 pathogens, particularly Ebola, Marburg, and Lassa viruses.

Original languageEnglish (US)
Pages (from-to)155-161
Number of pages7
JournalAssay and Drug Development Technologies
Volume12
Issue number3
DOIs
StatePublished - Apr 1 2014

Fingerprint

Nipah Virus
Sulfonamides
Lassa virus
Marburgvirus
Ebolavirus
Therapeutic Human Experimentation
Encephalitis
Drug Discovery
Virus Replication
Libraries
Antiviral Agents
Viruses
Therapeutics

ASJC Scopus subject areas

  • Drug Discovery
  • Molecular Medicine
  • Medicine(all)

Cite this

A BSL-4 high-throughput screen identifies sulfonamide inhibitors of Nipah virus. / Tigabu, Bersabeh; Rasmussen, Lynn; White, E. Lucile; Tower, Nichole; Saeed, Mohammad; Bukreyev, Alexander; Rockx, Barry; LeDuc, James; Noah, James W.

In: Assay and Drug Development Technologies, Vol. 12, No. 3, 01.04.2014, p. 155-161.

Research output: Contribution to journalArticle

Tigabu, Bersabeh ; Rasmussen, Lynn ; White, E. Lucile ; Tower, Nichole ; Saeed, Mohammad ; Bukreyev, Alexander ; Rockx, Barry ; LeDuc, James ; Noah, James W. / A BSL-4 high-throughput screen identifies sulfonamide inhibitors of Nipah virus. In: Assay and Drug Development Technologies. 2014 ; Vol. 12, No. 3. pp. 155-161.
@article{3a9f6ec41d8a4f798b108e6332ee0435,
title = "A BSL-4 high-throughput screen identifies sulfonamide inhibitors of Nipah virus",
abstract = "Nipah virus is a biosafety level 4 (BSL-4) pathogen that causes severe respiratory illness and encephalitis in humans. To identify novel small molecules that target Nipah virus replication as potential therapeutics, Southern Research Institute and Galveston National Laboratory jointly developed an automated high-throughput screening platform that is capable of testing 10,000 compounds per day within BSL-4 biocontainment. Using this platform, we screened a 10,080-compound library using a cell-based, high-throughput screen for compounds that inhibited the virus-induced cytopathic effect. From this pilot effort, 23 compounds were identified with EC50 values ranging from 3.9 to 20.0 μM and selectivities >10. Three sulfonamide compounds with EC50 values <12 μM were further characterized for their point of intervention in the viral replication cycle and for broad antiviral efficacy. Development of HTS capability under BSL-4 containment changes the paradigm for drug discovery for highly pathogenic agents because this platform can be readily modified to identify prophylactic and postexposure therapeutic candidates against other BSL-4 pathogens, particularly Ebola, Marburg, and Lassa viruses.",
author = "Bersabeh Tigabu and Lynn Rasmussen and White, {E. Lucile} and Nichole Tower and Mohammad Saeed and Alexander Bukreyev and Barry Rockx and James LeDuc and Noah, {James W.}",
year = "2014",
month = "4",
day = "1",
doi = "10.1089/adt.2013.567",
language = "English (US)",
volume = "12",
pages = "155--161",
journal = "Assay and Drug Development Technologies",
issn = "1540-658X",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - A BSL-4 high-throughput screen identifies sulfonamide inhibitors of Nipah virus

AU - Tigabu, Bersabeh

AU - Rasmussen, Lynn

AU - White, E. Lucile

AU - Tower, Nichole

AU - Saeed, Mohammad

AU - Bukreyev, Alexander

AU - Rockx, Barry

AU - LeDuc, James

AU - Noah, James W.

PY - 2014/4/1

Y1 - 2014/4/1

N2 - Nipah virus is a biosafety level 4 (BSL-4) pathogen that causes severe respiratory illness and encephalitis in humans. To identify novel small molecules that target Nipah virus replication as potential therapeutics, Southern Research Institute and Galveston National Laboratory jointly developed an automated high-throughput screening platform that is capable of testing 10,000 compounds per day within BSL-4 biocontainment. Using this platform, we screened a 10,080-compound library using a cell-based, high-throughput screen for compounds that inhibited the virus-induced cytopathic effect. From this pilot effort, 23 compounds were identified with EC50 values ranging from 3.9 to 20.0 μM and selectivities >10. Three sulfonamide compounds with EC50 values <12 μM were further characterized for their point of intervention in the viral replication cycle and for broad antiviral efficacy. Development of HTS capability under BSL-4 containment changes the paradigm for drug discovery for highly pathogenic agents because this platform can be readily modified to identify prophylactic and postexposure therapeutic candidates against other BSL-4 pathogens, particularly Ebola, Marburg, and Lassa viruses.

AB - Nipah virus is a biosafety level 4 (BSL-4) pathogen that causes severe respiratory illness and encephalitis in humans. To identify novel small molecules that target Nipah virus replication as potential therapeutics, Southern Research Institute and Galveston National Laboratory jointly developed an automated high-throughput screening platform that is capable of testing 10,000 compounds per day within BSL-4 biocontainment. Using this platform, we screened a 10,080-compound library using a cell-based, high-throughput screen for compounds that inhibited the virus-induced cytopathic effect. From this pilot effort, 23 compounds were identified with EC50 values ranging from 3.9 to 20.0 μM and selectivities >10. Three sulfonamide compounds with EC50 values <12 μM were further characterized for their point of intervention in the viral replication cycle and for broad antiviral efficacy. Development of HTS capability under BSL-4 containment changes the paradigm for drug discovery for highly pathogenic agents because this platform can be readily modified to identify prophylactic and postexposure therapeutic candidates against other BSL-4 pathogens, particularly Ebola, Marburg, and Lassa viruses.

UR - http://www.scopus.com/inward/record.url?scp=84898854289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898854289&partnerID=8YFLogxK

U2 - 10.1089/adt.2013.567

DO - 10.1089/adt.2013.567

M3 - Article

VL - 12

SP - 155

EP - 161

JO - Assay and Drug Development Technologies

JF - Assay and Drug Development Technologies

SN - 1540-658X

IS - 3

ER -